Advanced search

Vol 28, No 5 (2021)
Review Article
Published online: 2020-09-21

open access

View PDF Download PDF file
Page views 13177
Article views/downloads 1649
Get Citation

Connect on Social Media

Connect on Social Media

Small vessel coronary artery disease: How small can we go with myocardial revascularization?

Maciej T. Wybraniec12, Paweł Bańka12, Tomasz Bochenek12, Tomasz Roleder3, Katarzyna Mizia-Stec12
DOI: 10.5603/CJ.a2020.0127
Pubmed: 32986235
Cardiol J 2021;28(5):767-778.

Abstract

The issue of small coronary artery atherosclerosis represents an intriguing aspect of coronary artery disease, which is related with higher rates of peri- and post-procedural complications and impaired long-term outcome. This problem is further complicated by the unclear definition of small coronary vessel. Recent randomized controlled trials have provided new data on possible novel interventional treatment of small coronary vessels with drug-coated balloons instead of traditional new-generation drug-eluting stent implantation. Also, the conservative management represents a therapeutic option in light of the results of the recent ISCHEMIA trial. The current article provides an overview of the most appropriate definition, interventional management, and prognosis of small coronary artery atherosclerosis.

Keywords: small coronary artery diseasesmall coronary vesselsmall vessel diseasedrug-coated balloonsdrug-eluting stents

Article available in PDF format

View PDF Download PDF file

References

  1. Biondi-Zoccai G, Sangiorgi G, Antoniucci D, et al. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients. Int J Cardiol. 2007; 117(3): 349–354.
    CrossRef
  2. Akiyama T, Moussa I, Reimers B, et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol. 1998; 32(6): 1610–1618.
    CrossRefPubMed
  3. Scholz SS, Lauder L, Ewen S, et al. One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. Clin Res Cardiol. 2020; 109(7): 845–856.
    CrossRefPubMed
  4. Elezi S, Kastrati A, Neumann FJ, et al. Vessel Size and Long-Term Outcome After Coronary Stent Placement. Circulation. 1998; 98(18): 1875–1880.
    CrossRef
  5. van der Heijden LC, Kok MM, Danse PW, et al. Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial. Am Heart J. 2016; 176: 28–35.
    CrossRefPubMed
  6. Briguori C, Tobis J, Nishida T, et al. Discrepancy between angiography and intravascular ultrasound when analysing small coronary arteries. Eur Heart J. 2002; 23(3): 247–254.
    CrossRefPubMed
  7. Biondi-Zoccai G, Moretti C, Abbate A, et al. Percutaneous coronary intervention for small vessel coronary artery disease. Cardiovasc Revasc Med. 2010; 11(3): 189–198.
    CrossRefPubMed
  8. Dortimer AC, Shenoy PN, Shiroff RA, et al. Diffuse coronary artery disease in diabetic patients: fact or fiction? Circulation. 1978; 57(1): 133–136.
    CrossRefPubMed
  9. Mosseri M, Yarom R, Gotsman MS, et al. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation. 1986; 74(5): 964–972.
    CrossRefPubMed
  10. Acharjee S, Teo KK, Jacobs AK, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356(15): 1503–1516.
    CrossRefPubMed
  11. Ong P, Safdar B, Seitz A, et al. Diagnosis of coronary microvascular dysfunction in the clinic. Cardiovasc Res. 2020; 116(4): 841–855.
    CrossRefPubMed
  12. Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart. 2018; 104(4): 284–292.
    CrossRefPubMed
  13. Rogers JH, Lasala JM. Coronary artery dissection and perforation complicating percutaneous coronary intervention. J Invasive Cardiol. 2004; 16(9): 493–499.
    PubMed
  14. Ndrepepa G, Berger P, Mehilli J, et al. Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions. J Am Coll Cardiol. 2008; 51(7): 690–697.
    CrossRef
  15. Rathore S, Terashima M, Katoh O, et al. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. EuroIntervention. 2009; 5(3): 349–354.
    CrossRefPubMed
  16. Brodie B, Pokharel Y, Garg A, et al. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2012; 5(10): 1043–1051.
    CrossRefPubMed
  17. Lee CH, Kang DY, Han M, et al. IRIS-DES Registry Investigators. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients. Int J Cardiol. 2019; 282: 17–23.
    CrossRefPubMed
  18. Agostoni P, Biondi-Zoccai GGL, Gasparini GL, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J. 2005; 26(9): 881–889.
    CrossRefPubMed
  19. Jeger RV, Farah A, Ohlow MA, et al. BASKET-SMALL 2 Investigators. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018; 392(10150): 849–856.
    CrossRefPubMed
  20. Doucet S, Schalij MJ, Vrolix MC, et al. Stent In Small Arteries(SISA) Trial Investigators. Stent placement to prevent restenosis after angioplasty in small coronary arteries. Circulation. 2001; 104(17): 2029–2033.
    PubMed
  21. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-Eluting vs uncoated stents for prevention of restenosis in small coronary arteries. JAMA. 2004; 292(22): 2727.
    CrossRef
  22. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
    CrossRefPubMed
  23. Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
    CrossRefPubMed
  24. Hau WK. Fractional flow reserve and complex coronary pathologic conditions. Eur Heart J. 2004; 25(9): 723–727.
    CrossRefPubMed
  25. Costa MA, Sabate M, Staico R, et al. Anatomical and physiologic assessments in patients with small coronary artery disease: final results of the Physiologic and Anatomical Evaluation Prior to and After Stent Implantation in Small Coronary Vessels (PHANTOM) trial. Am Heart J. 2007; 153(2): 296.e1–296.e7.
    CrossRefPubMed
  26. Puymirat E, Peace A, Mangiacapra F, et al. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary revascularization in patients with small-vessel disease. Circ Cardiovasc Interv. 2012; 5(1): 62–68.
    CrossRefPubMed
  27. Tu S, Westra J, Yang J, et al. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography. JACC: Cardiovascular Interventions. 2016; 9(19): 2024–2035.
    CrossRef
  28. Erbay A, Steiner J, Lauten A, et al. Assessment of intermediate coronary lesions by fractional flow reserve and quantitative flow ratio in patients with small-vessel disease. Catheter Cardiovasc Interv. 2019 [Epub ahead of print].
    CrossRefPubMed
  29. Zhuang B, Wang S, Zhao S, et al. Computed tomography angiography-derived fractional flow reserve (CT-FFR) for the detection of myocardial ischemia with invasive fractional flow reserve as reference: systematic review and meta-analysis. Eur Radiol. 2020; 30(2): 712–725.
    CrossRefPubMed
  30. Li L, Wang Li, Zhai CJ, et al. Clinical utility of intravascular ultrasonography-guided therapy in a small-vessel coronary lesion associated with Type 2 diabetes mellitus. Anatol J Cardiol. 2019; 22(2): 68–76.
    CrossRefPubMed
  31. Matsuo Y, Kubo T, Aoki H, et al. Optimal threshold of postintervention minimum stent area to predict in-stent restenosis in small coronary arteries: An optical coherence tomography analysis. Catheter Cardiovasc Interv. 2016; 87(1): E9–EE14.
    CrossRefPubMed
  32. Kordish I, Philipp S, Boese D, et al. [Dissection of the right coronary artery as a complication after the IVUS procedure]. Herz. 2007; 32(7): 573–577.
    CrossRefPubMed
  33. Judith S. Hochman at the American Heart Association Annual Scientific Sessions (AHA 2019). , Philadelphia, PA, November, 16, 2019.
  34. Jia H, Dai J, Hou J, et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study). Eur Heart J. 2017; 38(11): 792–800.
    CrossRefPubMed
  35. Xing L, Yamamoto E, Sugiyama T, et al. EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report. Circ Cardiovasc Interv. 2017; 10(12).
    CrossRefPubMed
  36. Yano H, Horinaka S, Ishikawa M, et al. Efficacy of everolimus-eluting stent implantation in patients with small coronary arteries (≤2.5 mm): outcomes of 3-year clinical follow-up. Heart Vessels. 2017; 32(7): 796–803.
    CrossRefPubMed
  37. https://www.bostonscientific.com/en-US/products/catheters--balloon/apex-ptca-dilatation-catheter.html (Date of entry: 30.03.2020).
  38. https://www.medtronic.com/us-en/healthcare-professionals/products/cardiovascular/coronary-balloons/sprinter-legend-rx-semicompliant.html (Date of entry: 30.03.2020).
  39. https://www.terumo-europe.com/en-emea/products/ryurei%E2%84%A2-ptca-dilatation-catheter (Date of entry: 30.03.2020).
  40. https://www.orbusneich.com/en/products/semi-compliant-balloons/sapphire (Date of entry: 30.03.2020).
  41. https://www.sis-medical.com/nic-nano-0-85-cto-balloon (Date of entry: 30.03.2020).
  42. Lee P, Kwon O, Ahn JM, et al. Safety and effectiveness of second-generation drug-eluting stents in Patients with left main coronary artery disease. J Am Coll Cardiol. 2018; 71(8): 832–841.
    CrossRef
  43. Briguori C, Sarais C, Pagnotta P, et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol. 2002; 40(3): 403–409.
    CrossRefPubMed
  44. Brugaletta S, Sabate M. Percutaneous treatment of extremely small coronary vessels: does size matter in terms of performance? JACC Cardiovasc Interv. 2017; 10(14): 1389–1391.
    CrossRefPubMed
  45. Rathore S. Small coronary vessel angioplasty: outcomes and technical considerations. Vasc Health Risk Manag. 2010; 6: 915–922.
    CrossRefPubMed
  46. Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation. 2005; 111(25): 3435–3442.
    CrossRefPubMed
  47. Ellis SG, Popma JJ, Lasala JM, et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005; 45(8): 1193–1200.
    CrossRefPubMed
  48. Elezi S, Dibra A, Mehilli J, et al. Vessel size and outcome after coronary drug-eluting stent placement. J Am Coll Cardiol. 2006; 48(7): 1304–1309.
    CrossRef
  49. Schampaert E, Cohen EA, Schlüter M, et al. C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004; 43(6): 1110–1115.
    CrossRefPubMed
  50. Siontis GCM, Piccolo R, Praz F, et al. Percutaneous coronary interventions for the treatment of stenoses in small coronary arteries: a network meta-analysis. JACC Cardiovasc Interv. 2016; 9(13): 1324–1334.
    CrossRefPubMed
  51. Kastrati A, Dirschinger J, Boekstegers P, et al. Influence of stent design on 1-year outcome after coronary stent placement: A randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv. 2000; 50(3): 290–297, doi: 10.1002/1522-726x(200007)50:3<290::aid-ccd5>3.0.co;2-w.
  52. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results. Circulation. 2001; 103(23): 2816–2821.
    CrossRef
  53. Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014; 100(2): 153–159.
    CrossRefPubMed
  54. Turco MA, Ormiston JA, Popma JJ, et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. JACC Cardiovasc Interv. 2008; 1(6): 699–709.
    CrossRefPubMed
  55. Lee JZ, Singh N, Ortega G, et al. Composite outcomes in 2.25-mm drug eluting stents: a systematic review. Cardiovasc Revasc Med. 2015; 16(4): 237–242.
    CrossRefPubMed
  56. Tam CC, Chan K, Lam S, et al. One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent. J Int Med Res. 2018; 46(1): 457–463.
    CrossRefPubMed
  57. Nestelberger T, Kaiser C, Jeger R. Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications. Expert Opin Drug Deliv. 2020; 17(2): 201–211.
    CrossRefPubMed
  58. Mohiaddin H, Wong TD, Burke-Gaffney A, et al. Drug-Coated balloon-only percutaneous coronary intervention for the treatment of de novo coronary artery disease: a systematic review. Cardiol Ther. 2018; 7(2): 127–149.
    CrossRefPubMed
  59. Kleber FX, Rittger H, Bonaventura K, et al. Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol. 2013; 102(11): 785–797.
    CrossRefPubMed
  60. Alfonso F, Scheller B. State of the art: balloon catheter technologies - drug-coated balloon. EuroIntervention. 2017; 13(6): 680–695.
    CrossRefPubMed
  61. Kufner S, Cassese S, Valeskini M, et al. ISAR-DESIRE 3 Investigators. Long-Term efficacy and safety of paclitaxel-eluting balloon for the treatment of drug-eluting stent restenosis: 3-year results of a randomized controlled trial. JACC Cardiovasc Interv. 2015; 8(7): 877–884.
    CrossRefPubMed
  62. Richelsen RK, Overvad TF, Jensen SE. Drug-Eluting balloons in the treatment of coronary de novo lesions: a comprehensive review. Cardiol Ther. 2016; 5(2): 133–160.
    CrossRefPubMed
  63. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels. J Am Coll Cardiol. 2012; 60(24): 2473–2480.
    CrossRef
  64. Giannini F, Latib A, Ancona MB, et al. A propensity score matched comparative study between paclitaxel-coated balloon and everolimus-eluting stents for the treatment of small coronary vessels. Catheter Cardiovasc Interv. 2017; 90(3): 380–386.
    CrossRefPubMed
  65. Sinaga DA, Ho HH, Watson TJ, et al. Drug-Coated balloons: a safe and effective alternative to drug-eluting stents in small vessel coronary artery disease. J Interv Cardiol. 2016; 29(5): 454–460.
    CrossRefPubMed
  66. Tian J, Tang Yd, Qiao S, et al. RESTORE SVD China Investigators. Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels: The RESTORE Small Vessel Disease China trial. Catheter Cardiovasc Interv. 2020; 95 Suppl 1: 587–597.
    CrossRefPubMed
  67. Silverio A, Buccheri S, Venetsanos D, et al. Percutaneous treatment and outcomes of small coronary vessels. JACC: Cardiovascular Interventions. 2020; 13(7): 793–804.
    CrossRef
  68. Megaly M, Rofael M, Saad M, et al. Outcomes with drug-coated balloons for treating the side branch of coronary bifurcation lesions. J Invasive Cardiol. 2018; 30(11): 393–399.
    PubMed
  69. Masiero G, Mojoli M, Ueshima D, et al. Current concepts on coronary revascularization using BRS in patients with diabetes and small vessels disease. J Thorac Dis. 2017; 9(Suppl 9): S940–S949.
    CrossRefPubMed
  70. Mahmoud AN, Barakat AF, Elgendy AY, et al. Long-Term efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2017; 10(5).
    CrossRefPubMed
  71. Stiehm M, Wüstenhagen C, Siewert S, et al. Impact of strut dimensions and vessel caliber on thrombosis risk of bioresorbable scaffolds using hemodynamic metrics. Biomed Tech (Berl). 2019; 64(3): 251–262.
    CrossRefPubMed
  72. Wiebe J, Baquet M, Dörr O, et al. Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. Int J Cardiol. 2020; 312: 42–47.
    CrossRefPubMed
  73. Hideo-Kajita A, Garcia-Garcia H, Kolm P, et al. Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II–III and BIOFLOW II trials. Int J Cardiol. 2020; 300: 60–65.
    CrossRef
  74. Serruys PW, Farooq V, Vranckx P, et al. A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. JACC Cardiovasc Interv. 2012; 5(6): 606–617.
    CrossRefPubMed
  75. O'Connor NJ, Morton JR, Birkmeyer JD, et al. Effect of coronary artery diameter in patients undergoing coronary bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation. 1996; 93(4): 652–655.
    CrossRefPubMed
  76. Rodriguez A, Rodríguez Alemparte M, Fernández Pereira C, et al. LASMAL investigators. Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results. Am J Med. 2005; 118(7): 743–751.
    CrossRefPubMed
  77. Schofer J, Schlüter M, Gershlick AH, et al. E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003; 362(9390): 1093–1099.
    CrossRefPubMed
  78. Mehilli J, Dibra A, Kastrati A, et al. Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries (ISAR-SMART 3) Study Investigators. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. 2006; 27(3): 260–266.
    CrossRefPubMed
  79. Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. 2010; 96(16): 1291–1296.
    CrossRefPubMed
  80. Sim HW, Ananthakrishna R, Chan SP, et al. Treatment of very small de novo coronary artery disease with 2.0 mm drug-coated balloons showed 1-year clinical outcome comparable with 2.0 mm drug-eluting stents. J Invasive Cardiol. 2018; 30(7): 256–261.
    PubMed
  81. Nishiyama N, Komatsu T, Kuroyanagi T, et al. Clinical value of drug-coated balloon angioplasty for de novo lesions in patients with coronary artery disease. Int J Cardiol. 2016; 222: 113–118.
    CrossRefPubMed
  82. Funatsu A, Nakamura S, Inoue N, et al. A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients with small vessel disease. Clin Res Cardiol. 2017; 106(10): 824–832.
    CrossRefPubMed
  83. Her AeY, Ann SH, Singh GB, et al. Comparison of paclitaxel-coated balloon treatment and plain old balloon angioplasty for de novo coronary lesions. Yonsei Med J. 2016; 57(2): 337–341.
    CrossRefPubMed
  84. Shin ES, Ann SH, Balbir Singh G, et al. Fractional flow reserve-guided paclitaxel-coated balloon treatment for de novo coronary lesions. Catheter Cardiovasc Interv. 2016; 88(2): 193–200.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Cardiology Journal

About Via Medica Advertising
Bookstore (Ikamed) TVMed
News
Copyright © 2023 Via Medica Regulations Cookie policy Privacy policy Legal Notice